Dainippon Buys Boston Biomedical To Build On Cancer Strategy
This article was originally published in PharmAsia News
Executive Summary
Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.